Study Of Role Of Lipoxin – A4 In Psoriasis

Document Type : Original Article

Authors

1 Dermatology and Andrology department, Faculty of Medicine, Beni-Suef University, Egypt.

2 Biochemistery department, Faculty of Medicine ,Cairo University, Egypt.

Abstract

The aim of this work was to evaluate the level of lipoxin – A4 (LXA4) in patients  with psoriasis and its correlation with clinical parameters. This study included 25 psoriatic patients who were recruited from the outpatient clinics of dermatology department, Faculty of Medicine, Beni-Suef University. In addition, 25 age and sex-matched volunteers were included as control group. Four mm punch skin biopsy will be taken from the tissue and will be kept in lysis solution for the stability of the studied parameters and will be kept frozen at -80°C till detection of LXA4 in tissue by real time-PCR. Peripheral blood samples for serum LXA4 are taken. Blood samples will be centrifuged and serum will be stored at 80°C and used for ELISA. The LPXA levels in the case ranged from 1.01 -7.8 ng/mL with a mean of 2.94 ±1.7 ng/mL. In addition, the LXA4 levels in the control ranged from 4.5 – 14.7 ng/mL with a mean of 9.45 ±2.26 ng/mL. The level of LXA4 is significantly downregulated in patients with psoriasis, compared to healthy volunteers. Moreover, the affection of LXA4 appears to be correlated with the severity of the diseases. LXA4 and its analogue may be potential therapeutic candidates for psoriasis.

Keywords

Main Subjects

References

  1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20. doi:10.3390/ijms20061475
  2. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018;45:264–72. doi:10.1111/1346-8138.14139.
  3. Brandon A, Mufti A, Gary Sibbald R. Diagnosis and management of cutaneous psoriasis: A review. Adv Ski Wound Care 2019;32:58–69. doi:10.1097/01.ASW.0000550592.08674.43.
  4. Lee EB, Amin M, Bhutani T, Wu JJ. Emerging therapies in psoriasis: A systematic review. Cutis 2018;101:5–9.
  5. Marginean A, Sharma-Walia N. Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi’s sarcoma cells. Transl Res 2015;166:111–33. doi:10.1016/j.trsl.2015.02.009.
  6. Liu X, Wang X, Duan X, Poorun D, Xu J, Zhang S, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis. Sci Rep 2017;7. doi:10.1038/s41598-017-07485-1.
  7. Hu F, Feng A ping, Liu X xin, Zhang S, Xu J tao, Wang X, et al. Lipoxin A4 inhibits lipopolysaccharide-induced production of inflammatory cytokines in keratinocytes by up-regulating SOCS2 and down-regulating TRAF6. J Huazhong Univ Sci Technol - Med Sci 2015a;35:426–31. doi:10.1007/s11596-015-1448-8.
  8. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277–94. doi:10.1016/j.anireprosci.2009.05.008.
  9. Hawkes JE, Feng BJ, Duffin KC. Genetics of psoriasis. Psoriatic Arthritis Psoriasis Pathol. Clin. Asp., 2016, p. 83–91. doi:10.1007/978-3-319-19530-8_10.
  10. Kimball, A. B., Gauthier, G., Hiscock, R., & Zhang, H. F. (2015). Psoriasis treatment patterns: phototherapy, oral nonbiologic, and biologic therapies. Am J Pharm Benefits, 7(2), e44-e52.
  11. Truong, B., Rich-Garg, N., Ehst, B. D., Deodhar, A. A., Ku, J. H., Vakil-Gilani, K., Danve, A., & Blauvelt, A. (2015). Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. Clinical, cosmetic and investigational dermatology, 8, 563–569. https://doi.org/10.2147/CCID.S90270
  12. Ghazy, A., Sadek, A., Kamel, A., & Tahoun, A. (2020). Serum clusterin in psoriasis: relation to metabolic syndrome. Al-Azhar International Medical Journal.
  13. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Prim 2016;2:16082. doi:10.1038/nrdp.2016.82.
  14. Kojanova, M., Fialova, J., Cetkovska, P., Gkalpakiotis, S., Jircikova, J., Dolezal, T., ... & Blahova, L. (2017). Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. International Journal of Dermatology, 56(4), 428-434.
  15. Xhaja, A., Shkodrani, E., Frangaj, S., Kuneshka, L., & Vasili, E. (2014). An epidemiological study on trigger factors and quality of life in psoriatic patients. Materia socio-medica, 26(3), 168.
  16. Islam, M. T., Paul, H. K., Zakaria, S. M., Islam, M. M., & Shafiquzzaman, M. (2011). Epidemiological determinants of psoriasis. Mymensingh medical journal: MMJ, 20(1), 9.
  17. Solmaz, D., Bakirci, S., Kimyon, G., Gunal, E. K., Dogru, A., Bayindir, O., ... & Cetin, G. Y. (2020). Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care & Research, 72(1), 63-68.
  18. Mohd Affandi, A., Khan, I., & Ngah Saaya, N. (2018). Epidemiology and clinical features of adult patients with psoriasis in Malaysia: 10-year review from the Malaysian Psoriasis Registry (2007–2016). Dermatology research and practice, 2018.
  19. Iskandar, I. Y. K., Ashcroft, D. M., Warren, R. B., Yiu, Z. Z. N., McElhone, K., Lunt, M., ... & Smith, C. H. (2015). Demographics and disease characteristics of patients with psoriasis enrolled in the B ritish A ssociation of D ermatologists B iologic I nterventions R egister. British Journal of Dermatology, 173(2), 510-518.
  20. Lewandowska-Polak, A. M., Kubiak, M., Brzezinska, O., Pomorska, E., Kowalski, M. L., & Makowska, J. (2018). AB0051 The influence of anti-inflammatory lipoxin a4 on generation of cytokines by pbmcs of patients with psoriatic arthritis

 

Files

Share

How to cite

Statistics